Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Cellectis Announces Participation in Five Investor Conferences
04:34pm, Thursday, 26'th Aug 2021
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs u
Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript
03:33pm, Friday, 06'th Aug 2021
Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
04:30pm, Thursday, 05'th Aug 2021
• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
04:34pm, Thursday, 29'th Jul 2021
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs�
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
01:16pm, Tuesday, 13'th Jul 2021
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
07:30am, Thursday, 01'st Jul 2021
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest S
CRISPR: 4 Emerging Players
09:06am, Wednesday, 30'th Jun 2021
CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agr
Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside
01:00pm, Tuesday, 22'nd Jun 2021
Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer. Cellectis offers a spec
• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidat
Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021
02:30am, Wednesday, 02'nd Jun 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
04:30pm, Tuesday, 11'th May 2021
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
04:30pm, Thursday, 06'th May 2021
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary techno
Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021
04:39pm, Monday, 26'th Apr 2021
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).
Monthly information on share capital and company voting rights
04:30pm, Monday, 12'th Apr 2021
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis Completes Sale of $47 million through its ATM program
02:30am, Friday, 09'th Apr 2021
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary tech
